半月神经节脉冲射频治疗头面部带状疱疹相关神经痛的疗效分析

Analysis of the clinical efficacy of Gasserian ganglion Pulsed Radiofrequency therapy on Facial Zoster Associated Neuralgia

摘要:

目的：回顾性分析半月神经节脉冲射频（Gasserian Ganglion Pulsed Radiofrequency, GG-PRF）治疗头面部带状疱疹相关神经痛 （Zoster Associated Neuralgia, ZAN） 的临床疗效以及影响其治疗效果的危险因素，旨在为GG-PRF治疗筛选治疗人群，预测远期治疗效果提供更有价值的参考意义。方法：收集2018年1月1日至2023年6月30日就诊于山东大学附属省立医院疼痛科，确诊为头面部ZAN并接受GG-PRF治疗病人临床资料。使用数字评定量表（Numerical Rating Scale, NRS）、简单睡眠指数记录病人治疗前、治疗完成后出院时、术后3月、术后6月、术后1年的疼痛程度及睡眠情况，并记录不良反应的发生情况。回顾性分析GG-PRF其临床疗效，使用单因素、多因素Logistic回归分析筛选可能影响疗效的因素。结果：共纳入70例病人，经GG-PRF治疗后，病人NRS评分显著降低（P＜0.001），睡眠质量显著改善（P＜0.001），整个治疗过程中仅出现2例不良反应，对症治疗后痊愈。Logistic回归分析表明病程（Course, OR 2.207, 95%CI 0.946-5.145, P=0.012）是影响GG-PRF治疗效果的独立危险因素。结论：GG-PRF治疗是治疗头面部ZAN安全而有效的办法，可有效缓解疼痛，改善患者睡眠质量，病程（Course）是影响治疗效果的独立危险因素，建议头面部ZAN的病人尽早治疗。

Abstract:

Objective: To explore the clinical efficacy of Gasserian Ganglion Pulsated Radiofrequency (GG-PRF) in the treatment of facial Zoster Associated Neuralgia (ZAN), as well as the risk factors that affect its therapeutic effect by retrospectively analysis. This study aims to provide more valuable reference for screening treatment populations and predicting long-term treatment outcomes for GG-PRF therapy. Methods: From January 1,2018 to June 30, 2023, clinical data of patients with facial ZAN and receiving GG-PRF treatment at Department of Pain Management of Shandong Provincial Hospital, Cheeloo College of Medicine were collected. The Numerical Rating Scale (NRS) and Simple Sleep Index were used to record the pain level and sleep status of patients before GG-PRF treatment, as well as at discharge, at 3 months, at 6 months, and 1 year after GG-PRF treatment. Simultaneously, the occurrence of adverse events during treatment were recorded. Retrospective analyze the clinical efficacy of GG-PRF, using univariate and multivariate logistic analysis to screen for factors that may affect efficacy. Results: A total of 70 patients were included in the analysis. The NRS scores significantly decreased (P<0.001), and the sleep quality significantly improved (P<0.001) after GG-PRF treatment. Only 2 adverse events occurred, and they recovered quickly after symptomatic treatment. The Logistic analysis showed that Course (OR 2.207, 95% CI 0.946-5.145, P=0.012) was the risk factor. Conclusion: GG-PRF treatment is safety and effective in the treatment of facial ZAN patients, which can effectively alleviate pain and improve sleep quality. Course is the risk factor affecting treatment effectiveness, it is recommended that patients with facial ZAN should be treated as early as possible.